Report of a case of anaplastic large cell lymphoma associated with a breast implant in a Brazilian patient BERNARDO 
Relato de caso de linfoma anaplásico de células grandes associado a implante mamário em paciente brasileira
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a T-cell lymphoproliferative disorder that has recently been recognized as an independent entity in the World Health Organization (WHO) classification of lymphomas.
Despite the small number of reports to date, the number of cases is rapidly increasing. Of the few hundred cases that have been reported so far, very few came from Brazil and none have been reported to the local authorities. We encountered a case of BIA-ALCL and believe that its report to the local plastic surgery community could raise awareness of this emerging pathology. The prognosis is very good in most of the diagnosed cases. However, little is known about how and why silicone implants could trigger a lymphoid response that results in ALCL. 
INTRODUCTION
Plastic surgeons worldwide have been surprised by the increasing number of women diagnosed with a new type of lymphoma that occurs in the presence of breast implants; the first such case was reported in 1997 1 . Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) has recently been included in the World Health Organization classification of lymphoid neoplasms 2 and remains a concern in modern plastic surgery practices 3 . Recent efforts to improve reporting and data analysis have been undertaken by regulatory agencies and medical societies globally [4] [5] [6] . Although Brazil is the second largest market for breast implants worldwide, no cases of BIA-ALCL have been officially reported to the Agência Nacional de Vigilância Sanitária (ANVISA) so far 7 . We encountered a case of BIA-ALCL recently and believe that its report will increase awareness of ALCL within the local plastic and breast surgery community.
CASE REPORT
A 44-year-old female patient presented to our clinic complaining of mild discomfort in her right breast for almost a year and recent enlargement of the same breast. The patient was otherwise healthy. She had undergone a primary periareolar breast augmentation with 195-cc bilateral polyurethane-coated implants 11 years previously.
There was marked volume asymmetry with discrete skin infiltration in the lower medial aspect of the breast (Figure 1 ). Physical examination and imaging revealed a 10-cm heterogeneous mass posterior to the implant that infiltrated the pectoralis major muscle (Figure 2 ). There was no seroma. The initial suspicion of BIA-ALCL was confirmed using an ultrasound-guided biopsy and pathological studies (CD30+; ALK-) ( Figure 3 A pre-operative positron emission tomography (PET) scan showed an increased glucose metabolism in the breast area (SUV = 9.5) and in an axillary lymph node. This node had been biopsied a few weeks earlier and no malignancy was detected (SUV = 2.0) ( Figure 4A ). Surgical planning and adjuvant therapy were discussed by a multidisciplinary team and with the patient, based on the best evidence available at the time.
The surgical procedure involved removal of the implant, total capsulectomy including the mass, and removal of all macroscopically suspicious tissue ( Figure 5 ). This resection included the pectoralis major muscle and part of the breast tissue and skin from the medial lower pole that had an abnormal appearance at inspection ( Figure 6 ). Reconstruction was achieved with an oncoplastic mammoplasty ( Figure 7) . The implant shell and polyurethane coating were intact. The right axilla was opened and manually explored for hard or enlarged nodes; however, none were found. Contralateral implant removal and capsulectomy were performed alongside conventional mastopexy. Pathological examination of the specimens from the right breast revealed infiltration of pleomorphic aberrant cells in the necrotic mass, adjacent muscle, breast tissue, and skin without a clear limit and positive margins. Additional skin removed for final shaping of the breast was clear of the aberrant lymphocytes; however, negative margins could not be guaranteed. The patient chose not to receive any adjuvant treatment. At the time, we did not feel that there was enough evidence to indicate any benefit from chemotherapy, and the patient refused radiotherapy. Nine months post-operatively, her PET scan shows complete remission of the disease ( Figure 4B ). This case was registered in the PROFILE Registry (http://www.thepsf. org/research/clinical-impact/profile.htm).
DISCUSSION
BIA-ALCL is a very rare complication of breast implants. However, given the number of Brazilian women with breast implants, every plastic and breast surgeon may encounter this emerging lymphoma. We still know very little about BIA-ALCL and the current evidence is limited to case reports and cross-sectional studies from the American, Australian, and British task forces. So far, a few hundred cases have been reported.
A study from the USA estimated the lifetime prevalence of BIA-ALCL to be 1 per 30,000 women with a textured breast implant 4 . BIA-ALCL has been reported in association with all types of textured implants; however, the Australian task force has suggested that implants from certain manufacturers present a much higher risk than others 5 . Late seroma has been the most frequently reported presentation of BIA-ALCL. However, late seromas in patients with breast implants are much more likely to be benign. Awareness of BIA-ALCL is important since diagnoses can only be made using specific immunohistochemistry studies of the fluid around the implant (CD30 and ALK staining).
Pathologists should be informed of the clinical suspicion and the specific tests required, as these are not routinely performed on specimens from the breast. In our case, the lymphoma presented as a mass, another presentation of the disease that has been reported. It is still unclear if these are different forms of the disease or part of a disease spectrum; however, the mass form of the disease has been associated with a poorer prognosis 3, 5, 6 . Removal of the implant with total capsulectomy seems to be sufficient to treat BIA-ALCL. Adjuvant radiotherapy and chemotherapy have been used in some of these patients, without a clear benefit. A recent guideline from the National Comprehensive Cancer Network proposed adjuvant treatment for BIA-ALCL not confined to the seroma fluid and capsule 8 . However, these adjuvant therapies have acute and lifelong morbidity that must be considered and discussed with the patient. Most of the current recommendations are still based on preliminary data and it will be a long time before we have solid evidence to guide clinical decision-making in patients presenting with BIA-ALCL.
In our case, the patient was very resistant to traditional oncological care and decided not to undergo radiation after multidisciplinary discussions. The followup period is short, although the patient is currently in remission. Very few deaths have occurred in patients with BIA-ALCL; mortality is believed to as low as 2.5%. Since the severity of clinical presentation and prior clinical suspicion are important sources of bias for reporting, this estimation is probably inflated.
The impact of this new entity on the breast surgery community is still unclear. The reactions of the public and the media to BIA-ALCL will depend on our efforts to generate information and to communicate properly.
